Verition Fund Management
CRNX icon

Verition Fund Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Verition Fund Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-95,333
Closed -$2.74M – 3794
2025
Q2 		$2.74M Buy
95,333
+68,875
+260% +$2.13M 0.01% 1687
2025
Q1 		$887K Buy
26,458
+9,241
+54% +$345K ﹤0.01% 2209
2024
Q4 		$880K Buy
+17,217
New +$963K ﹤0.01% 2135

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Verition Fund Management's CRNX Position: Q3 2025 in Review

Verition Fund Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 95,333 shares — an estimated $2.74M sold.

Verition Fund Management first reported a position in CRNX in Q4 2024 and held it in 3 quarters. The position peaked at $2.74M in Q2 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Verition Fund Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 95,333 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $2.74M.
  • Verition Fund Management first reported a position in Crinetics Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Verition Fund Management's Crinetics Pharmaceuticals position peaked at $2.74M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.